tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

LYPHF Stock Latest News

Luye Pharma’s New Phase 1 Study: A Potential Game-Changer in Neurological Treatments
Company AnnouncementsLuye Pharma’s New Phase 1 Study: A Potential Game-Changer in Neurological Treatments
2h ago
LYPHF
Luye Pharma’s New Trial on Tardive Dyskinesia: A Potential Game Changer?
PremiumCompany Announcements
Luye Pharma’s New Trial on Tardive Dyskinesia: A Potential Game Changer?
3h ago
LYPHF
Luye Pharma’s New Study on LY03017: A Potential Game-Changer in Neuropsychiatric Treatment
PremiumCompany Announcements
Luye Pharma’s New Study on LY03017: A Potential Game-Changer in Neuropsychiatric Treatment
3h ago
LYPHF
Luye Pharma’s Promising Phase III Trial for Relapsed SCLC: A Potential Game-Changer
PremiumCompany Announcements
Luye Pharma’s Promising Phase III Trial for Relapsed SCLC: A Potential Game-Changer
3h ago
LYPHF
Luye Pharma Converts Convertible Bonds to Shares
PremiumCompany Announcements
Luye Pharma Converts Convertible Bonds to Shares
2M ago
Luye Pharma Converts $25 Million of Tranche A Bonds
PremiumCompany AnnouncementsLuye Pharma Converts $25 Million of Tranche A Bonds
2M ago
Luye Pharma Reports Revenue Growth Amid Profit Decline
Premium
Company Announcements
Luye Pharma Reports Revenue Growth Amid Profit Decline
2M ago
Luye Pharma Reports Mixed Interim Financial Results for 2025
Premium
Company Announcements
Luye Pharma Reports Mixed Interim Financial Results for 2025
2M ago
Luye Pharma Announces Partial Conversion of Convertible Bonds
PremiumCompany Announcements
Luye Pharma Announces Partial Conversion of Convertible Bonds
2M ago
Luye Pharma Group to Review Interim Results and Dividend
PremiumCompany Announcements
Luye Pharma Group to Review Interim Results and Dividend
2M ago
Luye Pharma Completes Enrollment for Pioneering Anxiety Drug Trial
PremiumCompany Announcements
Luye Pharma Completes Enrollment for Pioneering Anxiety Drug Trial
2M ago
Luye Pharma Announces Partial Conversion of Convertible Bonds
PremiumCompany Announcements
Luye Pharma Announces Partial Conversion of Convertible Bonds
2M ago
Luye Pharma Converts Tranche A Bonds to Shares
PremiumCompany AnnouncementsLuye Pharma Converts Tranche A Bonds to Shares
3M ago
Luye Pharma Group Announces Successful AGM Results
Premium
Company Announcements
Luye Pharma Group Announces Successful AGM Results
5M ago
Luye Pharma Group Announces 2025 Annual General Meeting
Premium
Company Announcements
Luye Pharma Group Announces 2025 Annual General Meeting
6M ago
Luye Pharma Launches Rotigotine Patch in UK, Expands CNS Treatment Portfolio
PremiumCompany Announcements
Luye Pharma Launches Rotigotine Patch in UK, Expands CNS Treatment Portfolio
7M ago
Luye Pharma’s Antidepressant Ruoxinlin® Gains Approval in Macao
PremiumCompany Announcements
Luye Pharma’s Antidepressant Ruoxinlin® Gains Approval in Macao
7M ago
Luye Pharma’s Rivastigmine Patch Gains Approval in Japan
PremiumCompany Announcements
Luye Pharma’s Rivastigmine Patch Gains Approval in Japan
7M ago
Luye Pharma Reports Mixed Financial Results for 2024
PremiumCompany Announcements
Luye Pharma Reports Mixed Financial Results for 2024
7M ago
Luye Pharma Group Schedules Board Meeting to Approve Annual Results and Dividend
PremiumCompany AnnouncementsLuye Pharma Group Schedules Board Meeting to Approve Annual Results and Dividend
8M ago
Luye Pharma upgraded to Neutral from Sell at Goldman Sachs
Premium
The Fly
Luye Pharma upgraded to Neutral from Sell at Goldman Sachs
8M ago
Luye Pharma Initiates Phase II Trial for CNS Drug LY03015 in China
Premium
Company Announcements
Luye Pharma Initiates Phase II Trial for CNS Drug LY03015 in China
10M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >